Document Detail


Statins and vein graft failure in coronary bypass surgery.
MedLine Citation:
PMID:  22326889     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Saphenous vein grafts used in coronary artery bypass graft surgery suffer from lower patency rates compared to left internal mammary artery. A number of clinical trials and observational studies have demonstrated a significant benefit of statin treatment on vein graft patency. Aside from their well-known lipid-lowering capacities, statins exert pleiotropic effects by direct inhibition of the mevalonate pathway in the wall of these grafts. This leads to reduced geranylgeranylation of small GTPases such as Rho and Rac. Through this LDL-independent mechanism, statins improve endothelial function and reduce vascular inflammation and oxidative stress, inhibiting also smooth muscle cell proliferation and migration. Although the existing evidence supports a beneficial effect of statins on vein grafts biology, more clinical trials focused on the effect of aggressive statin treatment on vein graft patency are required, in order to safely translate this strategy into clinical practice.
Authors:
Marios Margaritis; Keith M Channon; Charalambos Antoniades
Related Documents :
3499279 - Evaluation of diseased coronary arterial branches by polar representations of thallium-...
6601199 - Congenital coronary arterial aneurysm without arteriovenous fistula resulting in myocar...
19097659 - Demonstration of a very rare coronary anomaly with multislice computed tomography: aris...
15919329 - Robotic totally endoscopic coronary artery bypass and catheter based coronary intervent...
20486959 - Long-term prognostic significance of coronary flow velocity reserve in patients with si...
8846479 - A new model for occluding the left coronary artery in the rabbit without thoracotomy.
2624789 - Congenital vascular rings: surgical management of 111 cases.
1157279 - The variable echocardiographic features in aortic valve endocarditis.
9821059 - Serum creatinine level is an independent risk factor for the angiographic severity of i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-02-10
Journal Detail:
Title:  Current opinion in pharmacology     Volume:  12     ISSN:  1471-4973     ISO Abbreviation:  Curr Opin Pharmacol     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-06-04     Completed Date:  2012-09-18     Revised Date:  2014-02-24    
Medline Journal Info:
Nlm Unique ID:  100966133     Medline TA:  Curr Opin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  172-80     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Coronary Artery Bypass*
Graft Occlusion, Vascular / prevention & control*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Saphenous Vein / transplantation
Thrombosis / prevention & control
Vascular Patency / drug effects
Grant Support
ID/Acronym/Agency:
090532//Wellcome Trust; FS/11/66/28855//British Heart Foundation; FS/11/66/28855//British Heart Foundation
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Different sympathetic pathways control the metabolism of distinct bone envelopes.
Next Document:  Hydrophobic mismatch of mobile transmembrane helices: Merging theory and experiments.